Herceptin

Herceptin is a prescription medication whose active ingredient is trastuzumab, supplied as a solution for subcutaneous injection. It is a humanized monoclonal antibody classified as an antineoplastic agent. Marketed in the European Union, Herceptin targets HER2‑positive cancers. The product is administered by a healthcare professional and is listed under ATC code L01XC03. It is not an over‑the‑counter drug and is administered in a clinical setting.

Herceptin is used in adult patients whose tumors show overexpression of the human epidermal growth factor receptor 2 (HER2). It is approved for both early‑stage and advanced disease settings.

- HER2‑positive early breast cancer, typically in combination with chemotherapy or as adjuvant therapy. - HER2‑positive metastatic breast cancer, often combined with taxane‑based chemotherapy. - HER2‑positive gastric or gastro‑esophageal adenocarcinoma, used with chemotherapy regimens. - HER2‑positive inflammatory breast cancer as part of a multimodal approach. - HER2‑positive disease in patients who have completed neoadjuvant therapy and require continued HER2 blockade.

Like other monoclonal antibodies, Herceptin can cause a range of adverse reactions, from mild infusion‑related symptoms to rare but serious events.

Common: - Fever, chills, or flu‑like symptoms during or shortly after injection. - Nausea, vomiting, or mild gastrointestinal upset. - Injection‑site pain, erythema, or swelling. - Fatigue or headache.

Serious: - Cardiac dysfunction, including reduced left ventricular ejection fraction. - Severe allergic reactions such as anaphylaxis or angioedema. - Thromboembolic events, including deep vein thrombosis or pulmonary embolism.

Herceptin requires careful monitoring because certain conditions can increase the risk of adverse outcomes or affect treatment efficacy.

- Assess baseline cardiac function (e.g., echocardiogram) before initiating therapy and periodically during treatment. - Avoid use in patients with known hypersensitivity to trastuzumab or any component of the formulation. - Use with caution in individuals with pre‑existing cardiac disease or uncontrolled hypertension. - Monitor for signs of infection, especially during concurrent chemotherapy. - Adjust or discontinue therapy if significant decline in left ventricular ejection fraction occurs. - Counsel women of childbearing potential about the risks of fetal harm and advise effective contraception.

Herceptin may interact with other medications, influencing its safety profile or therapeutic effect.

Avoid: - Concurrent use with anthracycline chemotherapy (e.g., doxorubicin) due to increased risk of cardiotoxicity. - Live vaccines during treatment, because immune modulation can reduce vaccine efficacy and increase infection risk.

Use with caution: - Other HER2‑targeted agents (e.g., pertuzumab, lapatinib) as combined therapy may heighten cardiac monitoring needs. - Medications that prolong QT interval, which could compound cardiac effects. - Hormonal therapies that affect cardiac function, requiring closer cardiac assessment.